甲状腺功能测试市场- 按产品（仪器、试剂和试剂盒）、测试类型（TSH 测试、T4 测试、T3 测试、免费T4 测试）、最终用途（医院和诊所、诊断实验室、研究和学术机构） - 全球预测（2024 - 2032）

甲状腺功能测试市场规模预计从 2024 年到 2032 年将以 6.1% 的复合年增长率扩大。根据美国癌症协会的资料，预计 2024 年美国将新增 44,020 例甲状腺癌病例。

诊断方法的重大进步进一步提高了准确性和效率，使测试变得更加容易和可靠。医疗保健基础设施的扩张，特别是在新兴经济体，正在改善诊断服务的取得。日益增长的老龄化人口更容易出现甲状腺问题，进一步加速了检测需求。多项政府措施和健康计画正在鼓励甲状腺疾病的早期发现、诊断和管理。预防性医疗实践的日益普及也对产业成长产生了积极影响。

市场分为产品、测试类型、最终用途和地区。

根据产品，在提高测试准确性和效率的诊断技术进步的带动下，仪器领域的甲状腺功能测试产业价值预计将在 2024 年至 2032 年间大幅成长。医疗保健提供者对早期诊断和监测的日益关注正在推动先进仪器的采用。对医疗保健基础设施的投资不断增加以及诊断实验室的扩张，特别是在新兴市场，将增加产品需求。

就最终用途而言，预计到 2032 年，诊断实验室领域的甲状腺功能检测市场将以显着速度增长。实验室设备的重大进步正在提高测试效率和精度。医疗保健基础设施投资的增加以及新兴市场诊断服务的扩张也将有利于该领域的成长。

从地区来看，由于人们对甲状腺疾病的认识不断提高以及医疗保健支出不断增加，预计亚太地区甲状腺功能检测市场规模将在 2024 年至 2032 年间大幅增长。甲状腺疾病的流行，加上诊断基础设施的改进，正在加速这些测试的部署。政府健康倡议和促进甲状腺疾病早期诊断和管理的计划的启动将进一步推动区域产业的发展。

目录

第 1 章：方法与范围

第 2 章：执行摘要

第 3 章：产业洞察

• 产业生态系统分析
• 产业影响力
  • 成长动力
    • 甲状腺疾病的发生率增加
    • 诊断技术的进步
    • 增加医疗保健支出
    • 筛检项目数量不断增加
  • 产业陷阱与挑战
    • 严格的监管场景
    • 诊断测试成本高
• 成长潜力分析
• 技术景观
• 监管环境
• 波特的分析
• PESTEL分析

第 4 章：竞争格局

• 介绍
• 公司矩阵分析
• 公司市占率分析
• 竞争定位矩阵
• 战略展望矩阵

第 5 章：市场估计与预测：按产品分类，2021 - 2032 年

• 主要趋势
• 仪器
• 试剂及试剂盒
• 其他产品

第 6 章：市场估计与预测：按测试类型，2021 - 2032 年

• 主要趋势
• TSH（促甲状腺激素）测试
• T4（甲状腺素）测试
• T3（碘甲状腺原氨酸）测试
• 免费T4测试
• 免费T3测试
• 其他测试类型

第 7 章：市场估计与预测：按最终用途，2021 - 2032 年

• 主要趋势
• 医院和诊所
• 诊断实验室
• 研究与学术机构
• 其他最终用户

第 8 章：市场估计与预测：按地区，2021 - 2032

• 主要趋势
• 北美洲
  • 我们
  • 加拿大
• 欧洲
  • 德国
  • 英国
  • 法国
  • 西班牙
  • 义大利
  • 欧洲其他地区
• 亚太地区
  • 日本
  • 中国
  • 印度
  • 澳洲
  • 韩国
  • 亚太地区其他地区
• 拉丁美洲
  • 巴西
  • 墨西哥
  • 阿根廷
  • 拉丁美洲其他地区
• 中东和非洲
  • 沙乌地阿拉伯
  • 南非
  • 阿联酋
  • 中东和非洲其他地区

第 9 章：公司简介

• Abbott Laboratories
• bioMerieux S.A.
• Bio-Rad Laboratories, Inc.
• Cipla Limited
• Danaher Corporation
• DiaSorin S.p.A.
• F. Hoffmann-La Roche Ltd.
• Quidelortho Corporation
• Randox Laboratories Ltd.
• Siemens Healthineers AG
• Thermo Fisher Scientific Inc.

Thyroid Function Testing Market size is projected to expand at 6.1% CAGR from 2024 to 2032. The growing prevalence of thyroid disorders like hypothyroidism and hyperthyroidism is necessitating regular monitoring and diagnosis. According to data from the American Cancer Society, the U.S. is projected to witness 44,020 new cases of thyroid cancer in 2024. The rising awareness about thyroid health and its impacts on overall well-being is also boosting the demand for testing techniques.

Significant advancements in diagnostic methods are further enhancing accuracy and efficiency, making tests more accessible and reliable. The expansion of healthcare infrastructure, particularly in emerging economies, is improving access to diagnostic services. The growing aging population is more susceptible to thyroid issues, further accelerating the testing demand. Multiple government initiatives and health programs are encouraging the early detection, diagnosis, and management of thyroid conditions. The increasing adoption of preventive healthcare practices is also positively influencing the industry growth.

The market is bifurcated into product, test type, end-use, and region.

Based on product, the thyroid function testing industry value from the instruments segment is estimated to rise at significant rate between 2024 and 2032, led by advancements in diagnostic technology for enhancing test accuracy and efficiency. The growing focus of healthcare providers on early diagnosis and monitoring is fueling the adoption of advanced instruments. The rising investments in healthcare infrastructure and the expansion of diagnostic laboratories, particularly in emerging markets will add to the product demand.

With respect to end-use, the thyroid function testing market from the diagnostic laboratories segment is estimated to grow at significant rate through 2032. This is due to the growing burden of thyroid disorders and the high demand for accurate, reliable testing. Significant advancements in laboratory equipment are improving testing efficiency and precision. The rising investments in healthcare infrastructure and the expansion of diagnostic services in emerging markets will also favor the segment growth.

Regionally, the Asia Pacific thyroid function testing market size is projected to witness substantial gains between 2024 and 2032, owing to the rising awareness of thyroid disorders and increasing healthcare expenditure. The prevalence of thyroid diseases, coupled with improved diagnostic infrastructure is accelerating the deployment of these tests. The launch of government health initiatives and programs for promoting the early diagnosis and management of thyroid conditions will further fuel the regional industry progression.

Table of Contents

Chapter 1 Methodology & Scope

• 1.1 Market scope & definitions
• 1.2 Research design
  • 1.2.1 Research approach
  • 1.2.2 Data collection methods
• 1.3 Base estimates & calculations
  • 1.3.1 Base year calculation
  • 1.3.2 Key trends for market estimation
• 1.4 Forecast model
• 1.5 Primary research and validation
  • 1.5.1 Primary sources
  • 1.5.2 Data mining sources

Chapter 2 Executive Summary

• 2.1 Industry 360 degree synopsis

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Increasing incidence of thyroid disorders
    • 3.2.1.2 Advancements in diagnostic technologies
    • 3.2.1.3 Increasing healthcare expenditure
    • 3.2.1.4 Rising number of screening programs
  • 3.2.2 Industry pitfalls & challenges
    • 3.2.2.1 Stringent regulatory scenario
    • 3.2.2.2 High cost of diagnostic tests
• 3.3 Growth potential analysis
• 3.4 Technological landscape
• 3.5 Regulatory landscape
• 3.6 Porter's analysis
• 3.7 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

• 4.1 Introduction
• 4.2 Company matrix analysis
• 4.3 Company market share analysis
• 4.4 Competitive positioning matrix
• 4.5 Strategy outlook matrix

Chapter 5 Market Estimates and Forecast, By Product, 2021 - 2032 ($ Mn)

• 5.1 Key trends
• 5.2 Instruments
• 5.3 Reagent & kits
• 5.4 Other products

Chapter 6 Market Estimates and Forecast, By Test Type, 2021 - 2032 ($ Mn)

• 6.1 Key trends
• 6.2 TSH (thyroid stimulating hormone) test
• 6.3 T4 (thyroxine) test
• 6.4 T3 (riiodothyronine) test
• 6.5 Free T4 test
• 6.6 Free T3 test
• 6.7 Other test types

Chapter 7 Market Estimates and Forecast, By End-Use, 2021 - 2032 ($ Mn)

• 7.1 Key trends
• 7.2 Hospitals & clinics
• 7.3 Diagnostic laboratories
• 7.4 Research & academic institutes
• 7.5 Other end-users

Chapter 8 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)

• 8.1 Key trends
• 8.2 North America
  • 8.2.1 U.S.
  • 8.2.2 Canada
• 8.3 Europe
  • 8.3.1 Germany
  • 8.3.2 UK
  • 8.3.3 France
  • 8.3.4 Spain
  • 8.3.5 Italy
  • 8.3.6 Rest of Europe
• 8.4 Asia Pacific
  • 8.4.1 Japan
  • 8.4.2 China
  • 8.4.3 India
  • 8.4.4 Australia
  • 8.4.5 South Korea
  • 8.4.6 Rest of Asia Pacific
• 8.5 Latin America
  • 8.5.1 Brazil
  • 8.5.2 Mexico
  • 8.5.3 Argentina
  • 8.5.4 Rest of Latin America
• 8.6 Middle East and Africa
  • 8.6.1 Saudi Arabia
  • 8.6.2 South Africa
  • 8.6.3 UAE
  • 8.6.4 Rest of Middle East and Africa

Chapter 9 Company Profiles

• 9.1 Abbott Laboratories
• 9.2 bioMerieux S.A.
• 9.3 Bio-Rad Laboratories, Inc.
• 9.4 Cipla Limited
• 9.5 Danaher Corporation
• 9.6 DiaSorin S.p.A.
• 9.7 F. Hoffmann-La Roche Ltd.
• 9.8 Quidelortho Corporation
• 9.9 Randox Laboratories Ltd.
• 9.10 Siemens Healthineers AG
• 9.11 Thermo Fisher Scientific Inc.